Rare Diseases | Maple Syrup Urine | Ehlers-Danlos Syndrome

Acer Therapeutics is developing therapies for patients with serious, ultra-rare diseases with critical unmet need.

We are working to obtain FDA approval for Edsivo™ (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the US.

Dec. 20, 2016 – Acer Therapeutics Announces the Formation of its Scientific Advisory Board (SAB).

We are developing ACER-001 as the first potential therapy for Maple Syrup Urine Disease (MSUD); and for Urea Cycle Disorders (UCD)